SCHEMBL23523596

SCHEMBL23523596

COc1ccc(C(C)C(=O)c2ccc(N(C)C)cc2OC)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 10/20 0.62
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP3A4 P08684 2/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPT P10636 4/20 0.44
MAPK1 P28482 2/20 0.44
HSD17B10 Q99714 2/20 0.44
PPARG P37231 1/20 0.44
ALDH1A1 P00352 1/20 0.44
USP2 O75604 1/20 0.43
TLR9 Q9NR96 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30511137 1.00 HIF1A (0.62) HIF1AMEN1KMT2ACYP3A4LMNA
SCHEMBL30511127 0.85 HIF1A (0.79) HIF1AMEN1KMT2ACYP3A4LMNA
SCHEMBL23523355 0.85 HIF1A (0.79) HIF1AMEN1KMT2ACYP3A4LMNA
SCHEMBL23564661 0.85 HIF1A (0.79) HIF1AMEN1KMT2ACYP3A4LMNA
SCHEMBL23564660 0.84 HIF1A (0.49) HIF1AKMT2ACYP1A2CYP2C19L3MBTL1
SCHEMBL23564656 0.82 HIF1A (0.67) HIF1AMEN1KMT2ACYP3A4CYP1A2
SCHEMBL23523591 0.77 HIF1A (1.00) HIF1AMEN1KMT2ACYP3A4LMNA
SCHEMBL23564659 0.77 HIF1A (1.00) HIF1AMEN1KMT2ACYP3A4LMNA
SCHEMBL12970697 0.75 LMNA (0.57) MEN1KMT2ACYP3A4LMNACYP1A2
SCHEMBL23523652 0.75 HIF1A (1.00) HIF1AMEN1KMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12006283-B2 HIF-1α inhibitor, preparation method therefor, and pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as active ingredient SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2024-06-11 US disclosed
EP-3845516-A1 NOVEL HIF-1alfa INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT Seoul National University R & DB Foundation (KR) 2021-07-07 EP disclosed
US-20210188753-A1 NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KP) 2021-06-24 US disclosed
US-20210188753-A1 NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KP) 2021-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12006283-B2 HIF-1α inhibitor, preparation method therefor, and pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as active ingredient HIF1AN, HIF1A, EGLN2 HIF1A 2/4885MEN1 2805/4885KMT2A 1136/4885
US-20210188753-A1 NOVEL HIF-1ALPHA INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT HIF1AN, HIF1A, HYOU1 HIF1A 2/4885MEN1 3123/4885KMT2A 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.